13 panel drug screen test

13 panel drug screen test is a comprehensive tool widely used in medical, employment, and legal settings to detect the presence of multiple substances in an individual's system. This type of drug screening evaluates a wide range of drugs, providing a broad overview of recent or ongoing drug use. The 13 panel drug test is favored for its ability to screen for numerous substances at once, making it highly efficient and cost-effective. Understanding the substances tested, the testing methods, and the interpretation of results is crucial for employers, healthcare providers, and individuals undergoing testing. This article covers the essential aspects of the 13 panel drug screen test, including its purpose, substances detected, testing procedures, and the implications of the results. Additionally, the discussion will address the benefits and limitations of this testing method, helping readers gain a thorough understanding of the subject matter.

- Overview of the 13 Panel Drug Screen Test
- Substances Detected in the 13 Panel Drug Screen
- Testing Procedures and Methods
- Interpreting the Results of the 13 Panel Drug Test
- Benefits and Limitations of the 13 Panel Drug Screen
- Applications and Importance of the 13 Panel Drug Screen

Overview of the 13 Panel Drug Screen Test

The 13 panel drug screen test is an expanded drug testing method that checks for the presence of thirteen different substances or their metabolites in biological samples, typically urine. It builds upon more basic drug tests such as 5 or 10 panel screens by including additional substances for a more comprehensive assessment. The test is designed to identify both commonly abused drugs and prescription medications that have potential for misuse. Due to its broad scope, the 13 panel drug screen test is widely used in workplace drug testing programs, probation monitoring, pain management clinics, and pre-employment screenings. The testing process is usually rapid and can be conducted with high accuracy in certified laboratories or with point-of-care testing kits.

Purpose of the 13 Panel Drug Screen

The primary purpose of the 13 panel drug screen test is to detect and monitor drug use to ensure safety, compliance, and appropriate treatment. Employers use this test to maintain a drug-free workplace, while healthcare providers apply it to manage patient care effectively. Legal authorities may also require drug testing as part of probation or custody decisions. By identifying a wide spectrum of substances, the test helps in making informed decisions related to health, employment, and legal matters.

Substances Detected in the 13 Panel Drug Screen

The 13 panel drug screen test targets a variety of drugs, including illegal substances, prescription medications, and commonly abused drugs. Each panel corresponds to a specific drug or drug class, providing a detailed profile of an individual's recent substance use.

List of Drugs Typically Included

- Amphetamines (including methamphetamine)
- Cocaine
- Marijuana (THC)
- Opiates (such as morphine, codeine, and heroin)
- Phencyclidine (PCP)
- Benzodiazepines
- Barbiturates
- Methadone
- Propoxyphene
- Ecstasy (MDMA)
- Tricyclic Antidepressants (TCAs)
- Oxycodone
- Hydrocodone

This extensive range ensures detection of both illicit drug use and misuse of prescription medications, which is essential for comprehensive screening.

Testing Procedures and Methods

The 13 panel drug screen test is commonly conducted using urine samples, although other biological specimens such as saliva, blood, or hair can also be used depending on the context. Urine testing remains the most prevalent method due to its non-invasive collection process and high detection rates for most substances.

Sample Collection and Handling

Proper sample collection and handling are critical to ensure the accuracy and reliability of the test results. Collection typically occurs in a controlled environment to prevent tampering or substitution. The sample is then securely transported to a certified laboratory for analysis or tested on-site using rapid screening devices.

Laboratory Analysis Techniques

Laboratory testing of the 13 panel drug screen often involves immunoassay screening followed by confirmatory testing using methods such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). These confirmatory tests provide highly specific and sensitive identification of drug compounds and their metabolites, minimizing false positives and ensuring legal defensibility of the results.

Interpreting the Results of the 13 Panel Drug Test

Interpreting the results of a 13 panel drug screen requires understanding the meaning of positive, negative, and inconclusive outcomes. A positive result indicates the presence of a drug or metabolite above the established cutoff levels, while a negative result means no detectable levels were found. Inconclusive results may arise due to sample adulteration or insufficient sample quantity.

Factors Affecting Test Results

Several factors can influence the accuracy and interpretation of the test results, including:

- Timing of drug use relative to sample collection
- Metabolism rates of different individuals
- Cross-reactivity with certain medications or foods
- Sample contamination or adulteration

It is important to consider these variables when evaluating test outcomes to avoid misinterpretation and potential disputes.

Confirmatory Testing and Follow-Up

When an initial screening yields a positive result, confirmatory testing is recommended to verify the presence of specific drugs. This step is essential, especially in employment or legal contexts, to ensure fairness and accuracy. Follow-up testing or clinical evaluation may also be necessary based on the results and the purpose of the screening.

Benefits and Limitations of the 13 Panel Drug Screen

The 13 panel drug screen test offers numerous advantages but also has inherent limitations that must be understood by users.

Benefits

- Comprehensive detection of a wide range of substances
- Efficient and cost-effective screening
- Supports workplace safety and compliance
- Assists in clinical decision-making and treatment monitoring
- Legal defensibility with confirmatory testing protocols

Limitations

- Limited detection window depending on the substance and individual metabolism
- Possibility of false positives or negatives without confirmatory tests
- Does not detect all possible drugs or designer substances
- Potential privacy and ethical concerns in certain testing scenarios
- Requires proper sample collection and handling to ensure validity

Applications and Importance of the 13 Panel Drug Screen

The 13 panel drug screen test plays a vital role in various sectors by enhancing safety, compliance, and health outcomes. Its broad scope makes it suitable for multiple applications.

Workplace Drug Testing

Employers implement the 13 panel drug screen to maintain a drug-free workplace, reduce accidents, and promote productivity. Pre-employment, random, and post-incident testing are common practices supported by this test.

Medical and Clinical Use

Healthcare providers use the 13 panel drug screen to monitor patients prescribed controlled substances, detect potential drug abuse, and guide treatment plans, particularly in pain management and addiction treatment centers.

Legal and Forensic Settings

In legal contexts, the 13 panel drug screen assists in probation monitoring, child custody evaluations, and criminal investigations, ensuring compliance with court-ordered conditions and enhancing public safety.

Frequently Asked Questions

What is a 13 panel drug screen test?

A 13 panel drug screen test is a urine test that detects the presence of 13 different types of drugs or their metabolites in the body.

Which drugs are included in a 13 panel drug screen test?

Commonly tested drugs include amphetamines, cocaine, marijuana (THC), opiates, phencyclidine (PCP), benzodiazepines, barbiturates, methadone, methamphetamine, ecstasy (MDMA), oxycodone, propoxyphene, and tricyclic antidepressants.

How long does it take to get results from a 13 panel drug screen test?

Results from a 13 panel drug screen test typically take 24 to 72 hours, depending on the laboratory and testing method used.

Can a 13 panel drug screen test detect synthetic cannabinoids or fentanyl?

Most standard 13 panel drug tests do not detect synthetic cannabinoids or fentanyl; specialized tests are required for those substances.

How accurate is a 13 panel drug screen test?

A 13 panel drug screen test is generally accurate, but false positives or negatives can occur; confirmatory testing like GC-MS is recommended for definitive results.

Is the 13 panel drug screen test used for employment

screening?

Yes, many employers use 13 panel drug tests as part of pre-employment screening or random drug testing programs to ensure workplace safety.

Can prescription medications affect the results of a 13 panel drug screen test?

Yes, some prescription medications can trigger positive results; it is important to disclose any prescriptions to the testing administrator before the test.

How long do drugs stay detectable in a 13 panel drug screen test?

Detection times vary by drug but typically range from 1 to 7 days; chronic use can extend detection windows.

What should I do if I test positive on a 13 panel drug screen test?

If you test positive, you should request a confirmatory test, provide any prescription information, and consult with the testing authority or your healthcare provider for further guidance.

Additional Resources

1. Comprehensive Guide to 13 Panel Drug Screen Testing

This book offers an in-depth exploration of the 13 panel drug screen test, covering the scientific principles behind each drug detection method. It provides detailed protocols for sample collection, testing procedures, and result interpretation. Ideal for laboratory technicians and healthcare professionals, it also discusses common challenges and troubleshooting tips.

2. Understanding Drug Screening: Focus on 13 Panel Tests

Designed for medical practitioners and students, this book breaks down the components of the 13 panel drug screen test, explaining the significance of each drug included. It emphasizes the clinical applications and legal considerations of drug screening. The text includes case studies to illustrate real-world scenarios.

3. Laboratory Techniques in 13 Panel Drug Screening

Focusing on laboratory methodologies, this book details the various analytical techniques employed in 13 panel drug screening, including immunoassays and confirmatory tests like GC-MS. It highlights best practices for maintaining accuracy and reliability in results. Readers will find helpful charts and guidelines for quality control.

4. Drug Testing in the Workplace: Implementing 13 Panel Screens

This publication addresses the practical aspects of using 13 panel drug tests in occupational settings. It covers policy development, employee rights, and regulatory compliance to help organizations implement effective drug screening programs. The book also discusses how to handle positive results

ethically and legally.

5. Clinical Implications of 13 Panel Drug Screen Results

Targeted at clinicians, this book explains how to interpret 13 panel drug screen results within a healthcare context. It explores potential false positives and negatives, drug interactions, and patient counseling strategies. The author provides guidance on integrating test outcomes into treatment plans.

6. Advances in Toxicology: 13 Panel Drug Screening Technologies

This text reviews the latest technological advancements in drug detection, focusing on innovations that enhance the 13 panel drug screen test. It covers emerging biomarkers, rapid testing devices, and improvements in sensitivity and specificity. Researchers and lab managers will find this resource valuable for staying current.

7. Legal Perspectives on 13 Panel Drug Screening

A comprehensive resource on the legal framework surrounding drug screening, this book examines laws, regulations, and court cases related to 13 panel tests. It discusses privacy issues, consent requirements, and the admissibility of test results in various jurisdictions. Employers, lawyers, and policymakers will benefit from its insights.

- 8. Pediatric and Adolescent Drug Screening: Challenges with 13 Panel Tests
 Focusing on younger populations, this book addresses the particular challenges of using 13 panel drug screens in pediatric and adolescent care. It discusses ethical considerations, appropriate testing protocols, and interpretation nuances. The author also highlights prevention and intervention strategies based on screening outcomes.
- 9. Quality Assurance in 13 Panel Drug Screening Laboratories

This manual outlines the essential quality assurance practices necessary to ensure reliable and valid 13 panel drug screen results. It covers standard operating procedures, staff training, equipment maintenance, and proficiency testing. Laboratory supervisors and quality managers will find this guide essential for accreditation preparation.

13 Panel Drug Screen Test

Find other PDF articles:

 $\underline{https://admin.nordenson.com/archive-library-803/pdf?ID=kqm09-9424\&title=why-was-sand-a-health-threat-for-egypt.pdf}$

13 panel drug screen test: Basic Skills in Interpreting Laboratory Data Mr. Rohit Manglik, 2024-07-30 A diagnostic tool to help healthcare professionals accurately interpret common and complex laboratory results for better patient care.

13 panel drug screen test: Algorithmic Diagnosis of Symptoms and Signs Douglas R. Collins, R. Douglas Collins, 2012-11-05 Algorithmic Diagnosis of Symptoms and Signs: A Cost-Effective Approach Third Edition Designed for quick reference, the revised Third Edition of this handy pocket manual contains diagnostic algorithms to help you interpret more than 230 symptoms and signs. The ideal aid for the busy clinician, this portable resource promotes a cost-effective patient workup,

highlighting what tests to order and when to refer to a specialist. The Third Edition has been updated to include new algorithmic diagnosis that highlight several useful laboratory tests not included in prior editions, real case histories that help readers apply algorithms in clinical practice, and a new appendix that provides an extensive list of diagnostic tests to be ordered when faced with the most common symptoms. NEW to the Third Edition... * NEW algorithmic diagnosis highlights several useful laboratory tests not included in prior editions. * NEW case histories help you apply algorithms in clinical practice. * NEW appendix provides an extensive list of diagnostic tests to be ordered when faced with the most common symptoms. Make the right call... Pick up your copy today!

13 panel drug screen test: <u>Code of Federal Regulations</u>, 1994 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries.

13 panel drug screen test: Mandated Benefits 2019 Compliance Guide (IL) Buckley, 2018-12-26 State-by-State Guide to Human Resources Law is the most comprehensive, authoritative guide to the employment laws of the 50 states and the District of Columbia. It is designed to provide quick access to each state's laws on the expanding number of issues and concerns facing business executives and their advisors--the professionals in HR, compensation, and employee benefits who work in multijurisdictional environments. This #1 guide to HR law in every state will help you to: Find accurate answers - fast - with our easy-to-use format and full citation to authority Compare and contrast employment laws between states Ensure full regulatory compliance - and avoid legal entanglements Get instant access to clear coverage of key topics, including state health care reform initiatives, FMLA, same-sex unions, workers' comp - and much more! And much more! State by State Guide to Human Resources Law, 2018 Edition has been updated to include: In-depth coverage of the Supreme Court's recent same-sex marriage decision and its implications for employment law Discussion of three important Title VII cases involving pregnancy discrimination, religious discrimination, and the EEOC's statutory conciliation obligation Analysis of private sector employment discrimination charges filed with the EEOC during FY 2014, including charge statistics, with a breakdown by type of discrimination alleged Coverage of recent state and federal legislative efforts to prohibit employers from requiring employees and job applicants to disclose their passwords to social media and private e-mail accounts as a condition of employment Discussion of the Supreme Court's recent PPACA decision and its effect on the federal and state health insurance exchanges Update on the Domestic Workers' Bill of Rights, now enacted in six states Coverage of the growing trend to raise state minimum wage rates and to increase penalties for violations of wage and hour laws Update on workplace violence prevention efforts and related issues Coverage of state laws requiring employers to provide pregnant workers with reasonable accommodations, including longer or more frequent rest periods And much more Previous Edition: State by State Guide to Human Resources Law, 2018 Edition, ISBN 9781454883722Âċ

Ancillary Services Kent Lewandrowski, Patrick M. Sluss, 2016-11-29 This book is the first comprehensive text on utilization management in the clinical laboratory and other ancillary services. It provides a detailed overview on how to establish a successful utilization management program, focusing on such issues as leadership, governance, informatics, and application of utilization management tools. The volume also describes ways to establish utilization management programs for multiple specialties, including anatomic pathology and cytology, hematology, radiology, clinical chemistry, and genetic testing among other specialties. Numerous examples of specific utilization management initiatives are also described that can be imported to other heath care organizations. A chapter on utilization management in Canada is also included. Edited by an established national leader in utilization management, Utilization Management in the Clinical Laboratory and Other Ancillary Services is a valuable resource for physicians, pathologists, laboratory directors, hospital administrators, and medical insurance professionals looking to implement a utilization management program.

13 panel drug screen test: Workplace Drug Testing Alain G. Verstraete, 2011 This comprehensive text provides clear explanations of the effects of drugs on human performance and the need for workplace drug testing. It provides essential information on the regulatory and legal frameworks around the world, how to set policies and coverage of all aspects of drug analysis and the associated interpretation of results.Contents include:* epidemiology of drug use in the working population* the evidence base and guidelines for workplace drug testing* legal, regulatory aspects and policies for drugs and alcohol* urine and alternative sample collection process* analytical techniques and specimen adulteration.Case studies of successful programmes are also included to illustrate the principles discussed.Written by internationally acknowledged experts this informative book will be essential reading for anyone interested in workplace drug testing or setting up such a system including clinical and forensic toxicologists, occupational health physicians, nurses, human resources, drug counselling and treatment providers, analytical chemists and lawyers.Alain Verstraete is Professor at the Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium and Department Head of the Toxicology Laboratory of the Laboratory of Clinical Biology, Ghent University Hospital, Ghent, Belgium.

13 panel drug screen test: Drug Testing in School without CE Test - Item 7391,

13 panel drug screen test: On-Site Drug Testing Amanda J. Jenkins, Bruce A. Goldberger, 2002-01-28 It is at least a decade since scientists turned their imaginations to creating new compact, portable test instruments and self-contained test kits that could be used to analyze urine and saliva for alcohol, drugs, and their metabolites. Although the potential applications for such tests at the site of specimen collection, now called "on-site" or "point-of-care" testing, range far beyond hospital emergency rooms and law enforcement needs, it was catalyzed by the requirements of workplace drug testing and other drugs-of-abuse testing programs. These programs are now a minor national industry in the United States and in some western European countries, and cover populations as diverse as the military, incarcerated criminals, people suspected of driving under the influence of alcohol and other drugs, all athletes from college to professional ranks, and of course the general employed population, which is monitored for illegal drug use and numbers in the millions. It is not surprising, then, that the need for rapid and precise tests, conducted economically by trained professionals, has become a major goal. Current government approved and peer reviewed laboratory methods for urine analysis serve present needs very well and have become remarkably robust over the past twenty years, but the logistics of testing some moving populations, such as the military, the Coast Guard, workers on off-shore oil platforms, and athletes—perhaps the most mobile of these groups—are unacceptably cumbersome.

13 panel drug screen test: *Doping in Elite Sport* Wayne Wilson, 2001 This book is an examination of the failure to control the use of banned performance-enhancing drugs in international sport. It will help you understand the universal issues involved in enforcing and controlling this ever-growing problem.

13 panel drug screen test: Medical Fee Schedule, 1995

Dasgupta, 2019-01-10 Critical Issues in Alcohol and Drugs of Abuse Testing Amitava Dasgupta, 2019-01-10 Critical Issues in Alcohol and Drugs of Abuse Testing, Second Edition, addresses the general principles and technological advances for measuring drugs and alcohol, along with the pitfalls of drugs of abuse testing. Many designer drugs, for example, are not routinely tested in drugs of abuse panels and may go undetected in a drug test. This updated edition is a must-have for clinical pathologists, toxicologists, clinicians, and medical review officers and regulators, bridging the gap between technical and clinical information. Topics of note include the monitoring of pain management drugs, bath salts, spices (synthetic marijuana), designer drugs and date rape drugs, and more. - Serves as a ready resource of information for alcohol and drug testing - Ideal resource for making decisions related to the monitoring and interpretation of results - Includes concise content for clinical laboratory scientists, toxicologists and clinicians

13 panel drug screen test: Cumulated Index Medicus, 1989

13 panel drug screen test: The Army Lawyer, 1975

- 13 panel drug screen test: The Federal Labor-management and Employee Relations Consultant, 1991
 - 13 panel drug screen test: Title List of Documents Made Publicly Available , 1989
- 13 panel drug screen test: Basic Skills in Interpreting Laboratory Data Mary Lee, 2009-02-26 This new edition of Basic Skills in Interpreting Laboratory Data, 4th Edition is acase-based learning tool that will enhance your skills in clinical lab test interpretation. It provides fundamentals of interpreting lab test results not only for pharmacy students, but also for practitioners as an aid in assessing patient drug-treatment responses. It is the only text written by and for pharmacists and provides case studies and practical information on patient therapy. Since the publication of the third edition, much has changed—in the clinical lab and in the hospital pharmacy. Consequently, the new fourth edition incorporates significant revisions and a wealth of important new information. NEW TO THIS EDITION: Three new chapters including new information on men's health, women's health, and pharmacogenomics and laboratory tests. Mini-cases embedded in each chapter provide therapy-related examples and reinforce important points made in the text. Quickview Charts give an overview of important clinical information including reference ranges and critical values. Learning Points focus on a clinical application of a major concept present in the chapter.
 - **13 panel drug screen test:** The Massachusetts register, 1992-01-31
 - 13 panel drug screen test: Public Health Reports, 1996

vs Enterprise17.13.0), copy it into your layout, and use it to update

- 13 panel drug screen test: Health Services Reports, 1996
- 13 panel drug screen test: The Clinical Toxicology Laboratory Leslie M. Shaw, Tai C. Kwong, 2001

Related to 13 panel drug screen test
html - What is ? - Stack Overflow In html made by fckeditor i find the following character:
What is this character?
111
0300000 0000000000000000
$0.013 \\ 0.014 \\ 0.0000000000000000000000000000000000$
Shader
xml - What is HTML Entity ' '? - Stack Overflow I'm generating an XML Document object via
the DOMDocument class. In the process, some kind of whitespace within elements is being
converted into . It's pretty
13
<pre>python - Errno 13 Permission denied - Stack Overflow</pre>
Asked 8 years, 8 months ago Modified 2 years, 3 months ago Viewed 490k times
$\verb $
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
upgrade - How to download and offline install Visual Studio 2022 Go to the Visual Studio
2022 Release History page and download a particular fixed version bootstrapper (e.g.

Trying to understand CHAR(10) and CHAR(13) in SQL Server CR (13) + LF (10) combine to create 1 total carriage return. If you do it in the opposite order, the LF forces the CR to be on a new line, producing 2 carriage returns

html - What is ? - Stack Overflow In html made by fckeditor i find the following character: What is this character?

1000000013000000300000 00 13 0000 8 000 6000mAh 0000 AIOO 00000000 1000000013000000

UU13UU14UUUUUUUUU10UUUU? - UU UUUUUUU13U14UUUUUUUUUUUUUUUUUUUUUUUU
Shader 13 14
xml - What is HTML Entity ' '? - Stack Overflow I'm generating an XML Document object via
the DOMDocument class. In the process, some kind of whitespace within elements is being
converted into & amp; #13;. It's pretty
00 14 0 13 000000000 - 00 00000002022000iPhone 1400000000000000000iPhone 140iPhone
13iPhone 14_iPhone 14_iPhone 14 Pro
python - Errno 13 Permission denied - Stack Overflow Errno 13 Permission denied [duplicate]
Asked 8 years, 8 months ago Modified 2 years, 3 months ago Viewed 490k times
$\verb DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$
upgrade - How to download and offline install Visual Studio 2022 Go to the Visual Studio
2022 Release History page and download a particular fixed version bootstrapper (e.g.
vs Enterprise17.13.0), copy it into your layout, and use it to update
iPhone 13 [[][][][][][][][][][][][][][][][][][][
Trying to understand CHAR(10) and CHAR(13) in SQL Server CR (13) + LF (10) combine to
create 1 total carriage return. If you do it in the opposite order, the LF forces the CR to be on a new
line, producing 2 carriage returns
html - What is ? - Stack Overflow In html made by fckeditor i find the following character:
& #13; What is this character?
10000000130000003000000 00 13 0000 8 000 6000mAh 0000 AIO0 00000000 1000000013000000
Shader
xml - What is HTML Entity ' '? - Stack Overflow I'm generating an XML Document object via
the DOMDocument class. In the process, some kind of whitespace within elements is being
converted into & amp; #13;. It's pretty
00 14 0 13 000000000 - 00 00000002022000iPhone 1400000000000000000iPhone 140iPhone
13
<pre>python - Errno 13 Permission denied - Stack Overflow</pre>
Asked 8 years, 8 months ago Modified 2 years, 3 months ago Viewed 490k times
UUltraiiUltra
upgrade - How to download and offline install Visual Studio 2022 Go to the Visual Studio
2022 Release History page and download a particular fixed version bootstrapper (e.g
vs_Enterprise17.13.0), copy it into your layout, and use it to update
iPhone 13iPhone 13iPhone 13iPhone 13
Trying to understand CHAR(10) and CHAR(13) in SQL Server CR (13) + LF (10) combine to
create 1 total carriage return. If you do it in the opposite order, the LF forces the CR to be on a new
line, producing 2 carriage returns
html - What is ? - Stack Overflow In html made by fckeditor i find the following character:

& mp; #13; What is this character?

xml - What is HTML Entity ' '? - Stack Overflow I'm generating an XML Document object via the DOMDocument class. In the process, some kind of whitespace within elements is being

converted into . It's
13iPhone 14_iPhone 14_iPhone 14 Pro
<pre>python - Errno 13 Permission denied - Stack Overflow</pre>
Asked 8 years, 8 months ago Modified 2 years, 3 months ago Viewed 490k times
$ \verb $
upgrade - How to download and offline install Visual Studio 2022 Go to the Visual Studio
2022 Release History page and download a particular fixed version bootstrapper (e.g
vs_Enterprise17.13.0), copy it into your layout, and use it to update
$\mathbf{iPhone}\ \ 13\ \square$

Trying to understand CHAR(10) and CHAR(13) in SQL Server CR(13) + LF(10) combine to create 1 total carriage return. If you do it in the opposite order, the LF forces the CR to be on a new line, producing 2 carriage returns

Related to 13 panel drug screen test

Drug Testing Pivot: Top Test Manufacturer Replaces Marijuana With Fentanyl In Updated Screening Panel (Benzinga.com1y) Psychemedics' FDA-cleared 5-panel drug screen replaces marijuana with fentanyl in view of the growing acceptance of cannabis. Fentanyl is the most dangerous opioid-based substance in the U.S. today,

Drug Testing Pivot: Top Test Manufacturer Replaces Marijuana With Fentanyl In Updated Screening Panel (Benzinga.com1y) Psychemedics' FDA-cleared 5-panel drug screen replaces marijuana with fentanyl in view of the growing acceptance of cannabis. Fentanyl is the most dangerous opioid-based substance in the U.S. today,

Crown Bioscience launches large-scale organoid panel screening platform for accelerated preclinical oncology drug discovery (News Medical1y) Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidXplore TM. This large-scale

Crown Bioscience launches large-scale organoid panel screening platform for accelerated preclinical oncology drug discovery (News Medical1y) Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidXplore TM. This large-scale

Back to Home: https://admin.nordenson.com